Clinical trials for next-generation drugs should be patient-centric – STAT
In designing next-generation clinical trials, it is important to emphasize the broader needs of the patients taking part in them.
Related Articles
Pfizer to pay $60 million to settle claims that Biohaven paid kickbacks to doctors
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Trump’s restrictions spark chaos across health and science agencies
The Trump administration’s freeze on communications, travel, and diversity efforts has sowed chaos across federal health agencies.
Veteran researcher who was critical of U.S. response to Covid named acting NIH head
The Trump administration has appointed Matthew Memoli, a veteran researcher who was critical of the U.S. response to the Covid pandemic, as acting head of…
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
CMS withdraws appeal of UnitedHealth Medicare Advantage star ratings case
The decision comes as Trump paused some federal work and could help UnitedHealth generate bigger profits from the taxpayer-funded program.
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft report obtained by…
Trump freeze on NIH grant reviews alarms scientists, with long-term impact uncertain
While the National Institutes of Health employs 20,000-plus workers and spans 27 institutes and centers, the agency’s main job is to fund researchers
Neomorph, AbbVie strike $1.64 billion deal
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see new…
Pharmalittle: We’re reading about scrubbing diversity from the FDA website, a Novo scolding, and more
The purging of FDA web pages involving DEI has ensnared ones focused on diversity in clinical trials